# Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

> **NCT01026415** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 73 (actual)

## Conditions studied

- Carcinomas
- Disease, Hodgkin
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Non-Hodgkin
- Neoplasms

## Interventions

- **DRUG:** brentuximab vedotin
- **DRUG:** rifampin
- **DRUG:** midazolam
- **DRUG:** ketoconazole
- **DRUG:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT01026415
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2014-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026415, "Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01026415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*